User:Mr. Ibrahem/Lutetium (177Lu) vipivotide tetraxetan

Lutetium (177Lu) vipivotide tetraxetan, sold under the brand name Pluvicto, is a radioactive medication used to treat metastatic castration-resistant prostate cancer (mCRPC) that is prostate-specific membrane antigen (PSMA)-positive. It is given by injection into a vein.

Common side effects include tiredness, dry mouth, nausea, low hemoglobin, decreased appetite, and constipation. Other side effects may include radiation exposure, bone marrow suppression, infertility, and kidney problems. Use by males with pregnant partners may harm the baby. Vipivotide tetraxetan binds to PSMA-expressing tumor cells while the attached 177Lu destroys the cells by beta particle radiation.

Lutetium (177Lu) vipivotide tetraxetan was approved for medical use in the United States in 2022. In October 2022, Europe recommended its approval. In the United States it costs about 45,000 USD per dose as of 2022.